Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Arylacetamide deacetylase-like 2 (AADACL2) is a human protein encoded by the AADACL2 gene, located on chromosome 3q25.1[1][6]. It is composed of 401 amino acids, with a predicted molecular weight of approximately 46 kDa and an isoelectric point around 7.2[1][5]. AADACL2 has two Abhydrolase_3 domains encompassing most of its structure, which confer **carboxylic ester hydrolase activity**[1][2]. This protein is predicted to localize to the endoplasmic reticulum, and shows tissue-specific expression—highly enriched in skin, and lower levels detected in placenta, esophagus, small intestine, and colon[1]. While it is one of the top skin-enriched genes and may function as a secreted protein, it is not currently established as a therapeutic target or drug receptor. Experimental findings suggest decreased expression in allergic skin in response to nickel allergy, hinting at a possible role in skin immune responses, but its full biological or pathological significance in humans remains unclear[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Arylacetamide deacetylase-like 2 (AADACL2).